EuroArbo 2027

Bio upcoming

Bio upcoming

Rosa’s team investigates how insect-transmitted plant DNA geminiviruses manipulate their hosts to replicate and spread, and how these interactions ultimately lead to disease.
Rosa obtained her PhD from the University of Málaga and, after a postdoctoral period at The Sainsbury Laboratory in Norwich, UK, she established her independent research group at the Shanghai Center for Plant Stress Biology of the Chinese Academy of Sciences. In 2021, the team moved to the University of Tübingen, Germany, where Rosa is a professor. Since August 2026, she is also director of the Department of Plant Virology at the Max Planck Institute for Plant Breeding Research in Cologne.

Bio upcoming

Bio upcoming

Bio upcoming

Sumana Sanyal is a Professor of Molecular Pathology at the Sir William Dunn School of Pathology, University of Oxford. She completed her PhD at Cornell University, followed by a postdoctoral fellowship at the Whitehead Institute, MIT. Before moving to Oxford she held a Croucher Foundation-sponsored Assistant Professorship at the HKU-Pasteur Research Pole, University of Hong Kong. Her group uses proteomics and cell biology to study how flaviviruses such as Dengue and Zika remodel host membranes and evade immune detection. Her research has been funded by the Croucher Foundation, UKRI and the Wellcome Trust.

Marnix has more than 20 years’ experience in antiviral drug discovery and development, spanning target identification, discovery virology, translational science and early clinical development up to phase 2 clinical proof of concept.
He obtained his Ph.D. in Applied Biological Sciences at the University of Leuven (Belgium) in 2005 and joined Johnson & Johnson / Tibotec R&D, where over 20+ years he led teams of up to 100 scientists and delivered five clinical candidates across HIV, CMV, dengue, coronaviruses, flaviviruses and tuberculosis.
He led the discovery and development of mosnodenvir, a first-in-class, pan-serotype dengue antiviral advanced to Phase 2a clinical proof of concept; served as EFPIA lead of the EUR 75M IMI CARE coronavirus consortium; and led the BARDA coronavirus collaboration that identified the M protein as a new druggable target.
In April 2026 he co-founded 1ML Consultancy, advising pharma, biotech and international consortia on antiviral and vaccine R&D.
He is an author on 50+ peer-reviewed publications and received the 2019 ISAR William Prusoff Young Investigator Award.